Top Markets
#1 Purr Purr +63.76%
#2 Pons Pons +51.76%
#3 Smilek to the Bank Smilek to the Bank +50.56%
#4 Non-Playable Coin Non-Playable Coin +34.60%
#5 ApeX ApeX +29.89%
#6 Kinetiq Kinetiq +27.29%
#7 Morpho Morpho +24.45%
#8 StonkBroker StonkBroker +23.94%
#9 Cash Cat Cash Cat +23.07%
#10 OriginTrail OriginTrail +21.94%
Coin of the day
Purr Purr
सेटिंग्स
भाषा
हिन्दी
मुद्रा
USD
थीम
NGM Biopharmaceuticals, Inc. NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGM
शेयरों में रैंक #20909
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering... NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody designed to activate fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating both type 2 diabetes and NASH. NGM's pipeline further encompasses NGM120, an antagonist antibody targeting GFRAL, in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II development for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody (targeting immunoglobulin-like transcript 2/4) in Phase I/II trials for patients with advanced solid tumors. Additionally, the company is developing NGM831 and NGM438, both intended for the treatment of advanced solid tumors. NGM has established significant partnerships, including research, product development, and licensing agreements with Merck Sharp & Dohme Corp. A separate collaboration with Merck & Co., Inc. is dedicated primarily to creating new treatments for pressing unmet patient needs in retinal and cardiovascular-metabolic (CVM) diseases, such as heart failure. Established in 2007, NGM Biopharmaceuticals, Inc. maintains its corporate headquarters in South San Francisco, California.
शेयर मूल्य
$1.54
अंतिम समन्वयन: 2024-04-08
मार्केट कैप
$119.21M
बदलाव (1 दिन)
0.00%
बदलाव (1 वर्ष)
0.00%
देश
US
व्यापार NGM Biopharmaceuticals, Inc. (NGM)

श्रेणी

Healthcare
NGM Biopharmaceuticals, Inc. (NGM) के लिए P/B अनुपात
2026 को P/B अनुपात TTM: 0
NGM Biopharmaceuticals, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/B अनुपात (TTM) 0 है। 2026 के अंत में, कंपनी का P/B अनुपात 0 था।
NGM Biopharmaceuticals, Inc. के लिए 2026 से 2026 तक P/B अनुपात का इतिहास
हर वर्ष के अंत में P/B अनुपात
वर्ष P/B अनुपात परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।
समान कंपनियों या प्रतिस्पर्धियों के लिए P/B अनुपात
कंपनी P/B अनुपात P/B अनुपात में अंतर देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH